Galapagos N.V. (GLPG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Galapagos N.V. (GLPG) has a cash flow conversion efficiency ratio of -0.024x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-78.61 Million ≈ $-91.91 Million USD) by net assets (€3.25 Billion ≈ $3.80 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Galapagos N.V. for the company's overall valuation and market capitalisation.
Galapagos N.V. - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Galapagos N.V.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Galapagos N.V. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Galapagos N.V. ranked by their cash flow conversion efficiency. Explore Galapagos N.V. earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Yantai Zhenghai Magnetic Mat
SHE:300224
|
0.015x |
|
Kirloskar Brothers Limited
NSE:KIRLOSBROS
|
0.048x |
|
A.F.P. Habitat
SN:HABITAT
|
0.087x |
|
Xintai Ntrl Gas
SHG:603393
|
0.044x |
|
China Railway Construction Corporation Limited
F:4FF
|
0.045x |
|
Shanxi Zhangze Electric Power Co Ltd
SHE:000767
|
0.120x |
|
AbraSilver Resource Corp.
TO:ABRA
|
-0.603x |
|
Luoyang Longhua Heat Trans Energy
SHE:300263
|
0.024x |
Annual Cash Flow Conversion Efficiency for Galapagos N.V. (2004–2025)
The table below shows the annual cash flow conversion efficiency of Galapagos N.V. from 2004 to 2025. View current stock price of Galapagos N.V. for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €3.24 Billion ≈ $3.78 Billion |
€-197.01 Million ≈ $-230.32 Million |
-0.061x | +44.89% |
| 2024-12-31 | €2.90 Billion ≈ $3.39 Billion |
€-320.03 Million ≈ $-374.14 Million |
-0.110x | +23.93% |
| 2023-12-31 | €2.80 Billion ≈ $3.27 Billion |
€-405.97 Million ≈ $-474.62 Million |
-0.145x | +26.71% |
| 2022-12-31 | €2.53 Billion ≈ $2.95 Billion |
€-500.54 Million ≈ $-585.19 Million |
-0.198x | -3.96% |
| 2021-12-31 | €2.64 Billion ≈ $3.09 Billion |
€-503.83 Million ≈ $-589.03 Million |
-0.191x | -19.10% |
| 2020-12-31 | €2.67 Billion ≈ $3.12 Billion |
€-427.34 Million ≈ $-499.60 Million |
-0.160x | -114.34% |
| 2019-12-31 | €2.88 Billion ≈ $3.36 Billion |
€3.21 Billion ≈ $3.75 Billion |
1.116x | +1050.99% |
| 2018-12-31 | €1.21 Billion ≈ $1.42 Billion |
€-142.47 Million ≈ $-166.56 Million |
-0.117x | +19.24% |
| 2017-12-31 | €1.01 Billion ≈ $1.18 Billion |
€-147.03 Million ≈ $-171.89 Million |
-0.145x | -146.04% |
| 2016-12-31 | €758.70 Million ≈ $887.00 Million |
€239.40 Million ≈ $279.89 Million |
0.316x | +200.51% |
| 2015-12-31 | €365.00 Million ≈ $426.72 Million |
€-114.59 Million ≈ $-133.97 Million |
-0.314x | +14.35% |
| 2014-12-31 | €206.13 Million ≈ $240.99 Million |
€-75.56 Million ≈ $-88.33 Million |
-0.367x | -11835.82% |
| 2013-12-31 | €167.14 Million ≈ $195.40 Million |
€522.00K ≈ $610.27K |
0.003x | -99.42% |
| 2012-12-31 | €118.45 Million ≈ $138.48 Million |
€64.10 Million ≈ $74.94 Million |
0.541x | +634.28% |
| 2011-12-31 | €118.38 Million ≈ $138.39 Million |
€-11.99 Million ≈ $-14.02 Million |
-0.101x | +19.01% |
| 2010-12-31 | €148.51 Million ≈ $173.62 Million |
€-18.57 Million ≈ $-21.71 Million |
-0.125x | -316.03% |
| 2009-12-31 | €108.88 Million ≈ $127.29 Million |
€6.30 Million ≈ $7.37 Million |
0.058x | +159.47% |
| 2008-12-31 | €84.32 Million ≈ $98.58 Million |
€-8.21 Million ≈ $-9.60 Million |
-0.097x | -2687.95% |
| 2007-12-31 | €98.63 Million ≈ $115.30 Million |
€371.00K ≈ $433.74K |
0.004x | +104.43% |
| 2006-12-31 | €109.54 Million ≈ $128.07 Million |
€-9.31 Million ≈ $-10.88 Million |
-0.085x | -33.68% |
| 2005-12-31 | €61.14 Million ≈ $71.47 Million |
€-3.89 Million ≈ $-4.54 Million |
-0.064x | +75.68% |
| 2004-12-31 | €10.37 Million ≈ $12.12 Million |
€-2.71 Million ≈ $-3.17 Million |
-0.261x | -- |
About Galapagos N.V.
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory no… Read more